Adrian Rawcliffe, Chief Executive Officer at Adaptimmune Therapeutics PLC (ADAP), sold 19,758 shares at $5.67 ($112K) on 2021-01-19, disclosed to the SEC on 2021-01-19.
Open-market sale of $112k ADAP by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.67 | 9,879 | $56K | 50.0% |
| 2 | $5.67 | 9,879 | $56K | 50.0% |
| Total | $5.67 avg | 19,758 | $112K | 100% |
| Filing → |
| WVE | SELL | 2025-11-14 | $219K | — | Filing → |
| ADAP | SELL | 2025-01-17 | $18K | — | Filing → |
| ADAP | SELL | 2025-01-15 | $35K | — | Filing → |